European Leukemia Trial Registry
Trial: MEK 111759

More Details
Title Phase I/II Study on the MEK Inhibitor GSK1120212 in rel./ref. Leukemias
Scientific Title An Open-Label, Dose Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor GSK1120212 in Subjects with Relapsed or Refractory Leucemias
Short Title MEK 111759
Trialgroup NN
Type of Trial multicentric, single-group, open-label
Disease Acute lymphoblastic leukemia(ALL) All subtypes
Acute myeloid leukemia(AML) AML all subtypes without FAB M3
Age >= 18 years
Status No longer recruiting
Start of Recruitment 01.04.2011

principal investigator
Ottmann, Prof. Dr., Oliver
Tel: +49 (0)69 6301 87070
Fax: +49 (0)69 6301 4170

Shortprotocol Shortprotocol
created 06.12.2011 Johannes Kraus
changed 10.04.2013 Sina Hehn
ELIC European Leukemia Information Center | no responsibility is taken for correctness and completeness of this information | |